Ari Maizel Sells 7,500 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) insider Ari Maizel sold 7,500 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $184.44, for a total value of $1,383,300.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Axsome Therapeutics Stock Down 0.5%

AXSM opened at $185.96 on Friday. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50. The business has a 50 day simple moving average of $159.39 and a 200-day simple moving average of $133.27. The stock has a market capitalization of $9.37 billion, a P/E ratio of -39.82, a P/E/G ratio of 9.80 and a beta of 0.44. Axsome Therapeutics, Inc. has a 12 month low of $86.99 and a 12 month high of $191.50.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). The business had revenue of $170.99 million for the quarter, compared to analyst estimates of $162.96 million. Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The firm’s revenue was up 63.2% compared to the same quarter last year. On average, equities analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Key Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Piper Sandler is bullish ahead of a likely Auvelity label expansion by April 30, which would expand the approved uses for Axsome’s depression drug and could materially increase addressable market and sales expectations. Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30
• Positive Sentiment: HC Wainwright has increased some earnings estimates and reiterated a Buy rating with a $260 target, signaling conviction in Axsome’s medium-term revenue trajectory and valuation upside. This analyst support is likely propping up investor sentiment despite volatility. HC Wainwright Brokers Increase Earnings Estimates for AXSM
• Positive Sentiment: Related coverage from HC Wainwright and other outlets highlights expectations for strong price appreciation and has coincided with recent share strength, providing momentum that could support further gains if clinical and label catalysts materialize. HC Wainwright Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock
• Positive Sentiment: Axsome recently hit a new 12‑month high following analyst upgrades, reflecting elevated optimism from the sell side which can attract momentum and institutional interest. Axsome Therapeutics (NASDAQ:AXSM) Hits New 12-Month High Following Analyst Upgrade
• Neutral Sentiment: Analyst roundup pieces summarize diverse views from ~14 analysts; consensus leans positive but shows dispersion in price targets and timing, indicating investor outcomes depend heavily on upcoming regulatory/label and sales data. 3AXSM : Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts
• Negative Sentiment: HC Wainwright’s detailed model changes are mixed — while they raised several quarterly and FY2025 estimates and the target, they also trimmed forecasts for certain quarters (notably Q2 and Q3 adjustments). That mix introduces near-term earnings uncertainty that can create volatility until clinical/label outcomes and actual sales datapoints arrive.

Analyst Upgrades and Downgrades

AXSM has been the topic of a number of research analyst reports. Oppenheimer reissued an “outperform” rating and set a $220.00 price objective on shares of Axsome Therapeutics in a report on Wednesday, December 31st. Wells Fargo & Company boosted their price target on Axsome Therapeutics from $157.00 to $193.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 13th. Piper Sandler raised their price objective on Axsome Therapeutics from $148.00 to $223.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. UBS Group lifted their price objective on Axsome Therapeutics from $163.00 to $248.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Finally, HC Wainwright upped their target price on Axsome Therapeutics from $200.00 to $260.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Nineteen investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $203.17.

Institutional Trading of Axsome Therapeutics

A number of large investors have recently made changes to their positions in AXSM. Versant Capital Management Inc increased its position in Axsome Therapeutics by 20,300.0% during the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock worth $25,000 after purchasing an additional 203 shares in the last quarter. First Horizon Corp acquired a new stake in shares of Axsome Therapeutics during the 3rd quarter worth about $34,000. Optiver Holding B.V. boosted its stake in shares of Axsome Therapeutics by 82.3% during the 3rd quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock worth $35,000 after purchasing an additional 130 shares during the last quarter. Essex Investment Management Co. LLC purchased a new stake in shares of Axsome Therapeutics during the third quarter worth about $38,000. Finally, Advisory Services Network LLC purchased a new stake in shares of Axsome Therapeutics during the third quarter worth about $40,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.